View ValuationKaleido Biosciences 将来の成長Future 基準チェック /06現在、 Kaleido Biosciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Jan 30Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease (COPD) StudyKaleido Biosciences, Inc. has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the company's efforts.Price Target Changed • Nov 03Price target increased to US$15.60Up from US$14.33, the current price target is an average from 6 analysts. New target price is 231% above last closing price of US$4.71. Stock is down 26% over the past year. The company is forecast to post a net loss per share of US$2.25 next year compared to a net loss per share of US$2.44 last year.Price Target Changed • Oct 19Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 6 analysts. New target price is 210% above last closing price of US$4.62. Stock is down 38% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$2.44 last year.Major Estimate Revision • Aug 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.30m to US$2.05m. EPS estimate increased from -US$2.22 to -US$2.17 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$15.57 unchanged from last update. Share price fell 5.0% to US$5.83 over the past week.Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.11m to US$1.75m. EPS estimate increased from -US$2.25 to -US$2.22 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$16.44 to US$16.00. Share price rose 7.8% to US$6.23 over the past week.Major Estimate Revision • Jun 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.53m to US$2.11m. EPS estimate unchanged at -US$2.25 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target broadly unchanged at US$16.00. Share price was steady at US$6.73 over the past week.すべての更新を表示Recent updatesお知らせ • Apr 09+ 2 more updatesKaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing OperationsKaleido Biosciences, Inc. announced on April 8, 2022, the Board of Directors, voted to immediately wind-down and cease all of the Company’s ongoing operations. In connection with cessation of activities, the employment of all of the Company’s remaining employees was terminated effective immediately. As previously announced, the Company had initiated a strategic process, in an attempt to maximize shareholder value and engaged professional advisors, including an investment banker to act as a strategic advisor in the process. Unfortunately the strategic process did not result in the identification of any viable transactions, and given its limited remaining resources, the Company cannot continue operations and believes that the best alternative is an orderly wind-down process. The Company is evaluating additional details regarding the wind-down, and will provide further information when available.お知らせ • Apr 03Kaleido Biosciences, Inc. announced delayed annual 10-K filingOn 04/01/2022, Kaleido Biosciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 30Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease (COPD) StudyKaleido Biosciences, Inc. has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the company's efforts.Reported Earnings • Nov 03Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.65 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$23.1m (flat on 3Q 2020).Price Target Changed • Nov 03Price target increased to US$15.60Up from US$14.33, the current price target is an average from 6 analysts. New target price is 231% above last closing price of US$4.71. Stock is down 26% over the past year. The company is forecast to post a net loss per share of US$2.25 next year compared to a net loss per share of US$2.44 last year.Price Target Changed • Oct 19Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 6 analysts. New target price is 210% above last closing price of US$4.62. Stock is down 38% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$2.44 last year.Major Estimate Revision • Aug 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.30m to US$2.05m. EPS estimate increased from -US$2.22 to -US$2.17 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$15.57 unchanged from last update. Share price fell 5.0% to US$5.83 over the past week.Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.11m to US$1.75m. EPS estimate increased from -US$2.25 to -US$2.22 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$16.44 to US$16.00. Share price rose 7.8% to US$6.23 over the past week.Executive Departure • Aug 10Chairman of the Board Michael Bonney has left the companyOn the 9th of August, Michael Bonney's tenure as Chairman of the Board ended after 3.0 years in the role. We don't have any record of a personal shareholding under Michael's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.75 years, which is considered inexperienced in the Simply Wall St Risk Model.Major Estimate Revision • Jun 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.53m to US$2.11m. EPS estimate unchanged at -US$2.25 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target broadly unchanged at US$16.00. Share price was steady at US$6.73 over the past week.Price Target Changed • Jun 17Price target increased to US$17.83Up from US$16.14, the current price target is an average from 6 analysts. New target price is 177% above last closing price of US$6.43. Stock is down 13% over the past year.Major Estimate Revision • May 11Consensus revenue estimates fall to US$547.0kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$1.80m to US$547.0k. Forecast losses increased from -US$2.20 to -US$2.30 per share. Pharmaceuticals industry in the US expected to see average net income growth of 12% next year. Consensus price target broadly unchanged at US$16.43. Share price fell 8.6% to US$6.73 over the past week.Executive Departure • Apr 17Consultant has left the companyOn the 15th of April, Katharine Knobil's tenure as Consultant ended after less than a year in the role. We don't have any record of a personal shareholding under Katharine's name. Katharine is the only executive to leave the company over the last 12 months.Analyst Estimate Surprise Post Earnings • Mar 04Revenue and earnings miss expectationsRevenue missed analyst estimates by 92%. Earnings per share (EPS) also missed analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 618%, compared to a 27% growth forecast for the Pharmaceuticals industry in the US.分析記事 • Feb 09Is Kaleido Biosciences, Inc. (NASDAQ:KLDO) Popular Amongst Insiders?If you want to know who really controls Kaleido Biosciences, Inc. ( NASDAQ:KLDO ), then you'll have to look at the...お知らせ • Feb 04Kaleido Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $60.375 million.Kaleido Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $60.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,250,000 Price\Range: $11.5Is New 90 Day High Low • Jan 27New 90-day high: US$14.21The company is up 126% from its price of US$6.29 on 29 October 2020. The American market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period.お知らせ • Jan 26Kaleido Biosciences, Inc. Announces Resignation of Katharine Knobil as Chief Medical Officer and Head of Research and Development, Effective as of January 29, 2021On January 20, 2021, Kaleido Biosciences, Inc. and Katharine Knobil, M.D. reached a mutual agreement that Dr. Knobil will resign from her position as Chief Medical Officer and Head of Research and Development of the Company, effective as of January 29, 2021. Dr. Knobil is leaving the Company in order to pursue other opportunities and her decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. In connection with her departure, the Company and Dr. Knobil entered into a separation agreement and general release dated as of January 25, 2021.お知らせ • Jan 15Kaleido Biosciences, Inc. Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-To-Moderate COVID-19Kaleido Biosciences, Inc. announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 hours of testing positive for COVID-19 to either receive Supportive Self Care (SSC) or SSC plus Microbiome Metabolic Therapy (MMT™) candidate KB109 for two weeks and then followed for an additional three weeks. The planned interim analysis comprised approximately half of the total study population (n=176) and showed that KB109 was well tolerated, with a safety profile consistent with previous studies of MMT candidates and no unexpected treatment-related adverse events. For subjects reporting one or more comorbidities, the median time to resolution of the thirteen overall COVID-19 related symptoms was 18 days with KB109 plus SSC and 27 days with SSC alone. KB109 demonstrated a favorable safety and tolerability profile with no unexpected treatment-related adverse events or discontinuations related to treatment. Approximately 40 percent of the patients reported at least one comorbidity at baseline. The presence of comorbidity lengthened the time to resolution of symptoms, even in mild to moderate COVID-19 disease. In the SSC alone arm, median time to resolution of the thirteen overall COVID-19 related symptoms in patients with no comobitities was 14 days as compared with 27 days in patients with at least one comorbidity. No difference in median time to resolution of symptoms was observed with KB109 plus SSC for the overall population, although small differences between the arms were observed during the follow-up period. Median time to resolution of the thirteen overall COVID-19 related symptoms for patients with one or more comorbidity at baseline was 18 days for the KB109 plus SSC group as compared with 27 days with SSC alone. Kaleido also evaluated eight cardinal COVID-19 related symptoms as defined by the Centers for Disease Control and Prevention, which showed median time to resolution of symptoms among patients with one or more comorbidity at baseline was 15 days for the KB109 plus SSC group as compared with 27 days with SSC alone. The K031 study of 350 subjects is fully enrolled with results expected in the first quarter of 2021. Topline data from a smaller 50 subject study of KB109 is also expected in the first quarter of 2021.Is New 90 Day High Low • Jan 08New 90-day high: US$11.40The company is up 1.0% from its price of US$11.33 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.お知らせ • Jan 05Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19Kaleido Biosciences, Inc. announced that completion of enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 in the treatment of mild-to-moderate COVID-19. The multi-center, non-IND clinical study is designed to evaluate the effects of KB109 plus supportive self-care (SSC) compared to SSC alone for outpatients who are positive for SARs-Cov-2 and have symptoms. Study endpoints include safety and tolerability, biomarkers of the inflammatory response, and time to resolution of symptoms. The Kaleido KB109 development program involves two controlled, non-IND clinical studies including one study of 350 patients evaluating symptom resolution and one study of approximately 50 patients evaluating effects on microbiome composition and biomarkers of inflammatory response. Subjects are randomized to either receive SSC (the control group) or SSC plus KB109 for two weeks and then followed for a further three weeks. KB109 was selected for evaluation in COVID-19 studies based on its ability to increase microbiome production of short chain fatty acids, which act as modulators of the immune response.Price Target Changed • Dec 26Price target raised to US$14.00Up from US$12.60, the current price target is an average from 4 analysts. The new target price is 50% above the current share price of US$9.33. As of last close, the stock is up 69% over the past year.分析記事 • Dec 14Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...Major Estimate Revision • Nov 09Analysts update estimatesThe 2020 consensus revenue estimate increased from US$14.1m to US$18.0m. Earning per share (EPS) estimate was further reduced from -US$2.37 to -US$2.50 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 2.5% next year. The consensus price target was lowered from US$12.60 to US$11.60. Share price is up 17% to US$6.73 over the past week.Price Target Changed • Nov 05Price target lowered to US$11.60Down from US$12.60, the current price target is an average from 4 analysts. The new target price is 81% above the current share price of US$6.40. As of last close, the stock is up 1.7% over the past year.Analyst Estimate Surprise Post Earnings • Nov 03Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 1,101%, compared to a 32% growth forecast for the Pharmaceuticals industry in the US.Major Estimate Revision • Oct 23Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$17.7m to US$14.1m. Earning per share (EPS) estimate was unchanged from the last update at -US$2.37. The Pharmaceuticals industry in the US is expected to see an average net income growth of 8.0% next year. The consensus price target of US$12.60 was unchanged from the last update. Share price is down by 21% to US$6.97 over the past week.お知らせ • Oct 14Kaleido Biosciences, Inc. Announces Change of Role of Michael Bonney from Executive Chair of the Board to Chair of the BoardKaleido Biosciences, Inc. on October 9, 2020 changed Michael Bonney’s role from Executive Chair of the Board to Chair of the Board, effective as of October 13, 2020. The change in Bonney’s title was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.お知らせ • Oct 07Kaleido Biosciences, Inc. Provides Update on KB109 Clinical Data TimelineKaleido Biosciences, Inc. announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease. Updated projections for enrollment of the multi-center K031 clinical study of approximately 350 patients indicated that top-line data will be available in the first quarter of 2021. Previous projections had indicated the potential availability of top-line data from the study in the fourth quarter of 2020. Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome’s existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company’s initial MMT candidates are targeted, synthetic glycans that are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. Kaleido utilizes its discovery and development platform to study MMTs in microbiome samples to advance MMT candidates rapidly into clinical studies in healthy subjects and patients. These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the company conducts clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., in Phase 2 or later development.お知らせ • Oct 02+ 1 more updateKaleido Biosciences, Inc. Announces Management Changes, Effective October 13, 2020Kaleido Biosciences, Inc. announced that Daniel Menichella has been appointed President and a member of the company’s Board of Directors, effective October 13, 2020. Mr. Menichella succeeds Alison Lawton, who stepped down to attend to a family health matter but continued to work with the Company in the Office of the CEO alongside Executive Chair Mike Bonney. Mr. Menichella is an experienced Chief Executive Officer, having been hired as CEO of CureVac Inc.’s US subsidiary in January 2017 before taking over as CEO of the international company in June of 2018.お知らせ • Sep 30Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative ColitisKaleido Biosciences, Inc. announced that the first patient has been dosed in its clinical study evaluating Microbiome Metabolic Therapy (MMT) candidate KB295 in patients with mild-to-moderate ulcerative colitis (UC). UC is an inflammatory bowel disease that can cause debilitating symptoms, including abdominal pain, bowel urgency and diarrhea. Evidence suggests that a feature of UC is alteration of the gut microbiome, including an increase in inflammatory bacteria and decrease in commensal diversity which interfere with the normal immune response. In ex vivo studies, KB295 has demonstrated the ability to increase the production of short chain fatty acids and suppress the growth of inflammatory bacteria such as Enterobacteriaceae. This non-IND/non-CTA open label, single arm clinical study is expected to enroll approximately 30 patients with mild-to-moderate UC. Patients will receive KB295 for eight weeks titrated up to 40 g twice daily and then enter a one-month follow-up period. The study will evaluate the safety and tolerability of KB295 and other assessments including the Simple Clinical Colitis Activity Index (SCCAI) composite score, changes in microbiome composition and biomarkers of inflammation.Is New 90 Day High Low • Sep 24New 90-day low: US$5.09The company is down 35% from its price of US$7.79 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Kaleido Biosciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:KLDO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20211-90-78-77N/A9/30/20211-90-73-71N/A6/30/20211-90-74-72N/A3/31/20211-85-71-68N/A12/31/20201-82-66-62N/A9/30/20201-81-70-66N/A6/30/20200-80-71-67N/A3/31/2020N/A-86-74-71N/A12/31/2019N/A-86-79-76N/A9/30/2019N/A-88-78-74N/A6/30/2019N/A-83-73-69N/A3/31/2019N/A-71-64-60N/A12/31/2018N/A-62-49-46N/A9/30/2018N/A-51-43-41N/A6/30/2018N/A-40-35-33N/A3/31/2018N/A-33-29-28N/A12/31/2017N/A-28-24-22N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KLDOの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: KLDOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: KLDOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: KLDOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: KLDOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KLDOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 23:18終値2026/05/21 00:00収益2021/12/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kaleido Biosciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Taylor FeehleyChardan Capital Markets, LLCKeay NakaeChardan Capital Markets, LLCGbolahan Amusa BenzChardan Capital Markets, LLC4 その他のアナリストを表示
お知らせ • Jan 30Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease (COPD) StudyKaleido Biosciences, Inc. has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the company's efforts.
Price Target Changed • Nov 03Price target increased to US$15.60Up from US$14.33, the current price target is an average from 6 analysts. New target price is 231% above last closing price of US$4.71. Stock is down 26% over the past year. The company is forecast to post a net loss per share of US$2.25 next year compared to a net loss per share of US$2.44 last year.
Price Target Changed • Oct 19Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 6 analysts. New target price is 210% above last closing price of US$4.62. Stock is down 38% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$2.44 last year.
Major Estimate Revision • Aug 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.30m to US$2.05m. EPS estimate increased from -US$2.22 to -US$2.17 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$15.57 unchanged from last update. Share price fell 5.0% to US$5.83 over the past week.
Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.11m to US$1.75m. EPS estimate increased from -US$2.25 to -US$2.22 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$16.44 to US$16.00. Share price rose 7.8% to US$6.23 over the past week.
Major Estimate Revision • Jun 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.53m to US$2.11m. EPS estimate unchanged at -US$2.25 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target broadly unchanged at US$16.00. Share price was steady at US$6.73 over the past week.
お知らせ • Apr 09+ 2 more updatesKaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing OperationsKaleido Biosciences, Inc. announced on April 8, 2022, the Board of Directors, voted to immediately wind-down and cease all of the Company’s ongoing operations. In connection with cessation of activities, the employment of all of the Company’s remaining employees was terminated effective immediately. As previously announced, the Company had initiated a strategic process, in an attempt to maximize shareholder value and engaged professional advisors, including an investment banker to act as a strategic advisor in the process. Unfortunately the strategic process did not result in the identification of any viable transactions, and given its limited remaining resources, the Company cannot continue operations and believes that the best alternative is an orderly wind-down process. The Company is evaluating additional details regarding the wind-down, and will provide further information when available.
お知らせ • Apr 03Kaleido Biosciences, Inc. announced delayed annual 10-K filingOn 04/01/2022, Kaleido Biosciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 30Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease (COPD) StudyKaleido Biosciences, Inc. has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the company's efforts.
Reported Earnings • Nov 03Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.65 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$23.1m (flat on 3Q 2020).
Price Target Changed • Nov 03Price target increased to US$15.60Up from US$14.33, the current price target is an average from 6 analysts. New target price is 231% above last closing price of US$4.71. Stock is down 26% over the past year. The company is forecast to post a net loss per share of US$2.25 next year compared to a net loss per share of US$2.44 last year.
Price Target Changed • Oct 19Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 6 analysts. New target price is 210% above last closing price of US$4.62. Stock is down 38% over the past year. The company is forecast to post a net loss per share of US$2.17 next year compared to a net loss per share of US$2.44 last year.
Major Estimate Revision • Aug 20Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.30m to US$2.05m. EPS estimate increased from -US$2.22 to -US$2.17 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$15.57 unchanged from last update. Share price fell 5.0% to US$5.83 over the past week.
Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.11m to US$1.75m. EPS estimate increased from -US$2.25 to -US$2.22 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$16.44 to US$16.00. Share price rose 7.8% to US$6.23 over the past week.
Executive Departure • Aug 10Chairman of the Board Michael Bonney has left the companyOn the 9th of August, Michael Bonney's tenure as Chairman of the Board ended after 3.0 years in the role. We don't have any record of a personal shareholding under Michael's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.75 years, which is considered inexperienced in the Simply Wall St Risk Model.
Major Estimate Revision • Jun 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$2.53m to US$2.11m. EPS estimate unchanged at -US$2.25 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target broadly unchanged at US$16.00. Share price was steady at US$6.73 over the past week.
Price Target Changed • Jun 17Price target increased to US$17.83Up from US$16.14, the current price target is an average from 6 analysts. New target price is 177% above last closing price of US$6.43. Stock is down 13% over the past year.
Major Estimate Revision • May 11Consensus revenue estimates fall to US$547.0kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$1.80m to US$547.0k. Forecast losses increased from -US$2.20 to -US$2.30 per share. Pharmaceuticals industry in the US expected to see average net income growth of 12% next year. Consensus price target broadly unchanged at US$16.43. Share price fell 8.6% to US$6.73 over the past week.
Executive Departure • Apr 17Consultant has left the companyOn the 15th of April, Katharine Knobil's tenure as Consultant ended after less than a year in the role. We don't have any record of a personal shareholding under Katharine's name. Katharine is the only executive to leave the company over the last 12 months.
Analyst Estimate Surprise Post Earnings • Mar 04Revenue and earnings miss expectationsRevenue missed analyst estimates by 92%. Earnings per share (EPS) also missed analyst estimates by 3.9%. Over the next year, revenue is forecast to grow 618%, compared to a 27% growth forecast for the Pharmaceuticals industry in the US.
分析記事 • Feb 09Is Kaleido Biosciences, Inc. (NASDAQ:KLDO) Popular Amongst Insiders?If you want to know who really controls Kaleido Biosciences, Inc. ( NASDAQ:KLDO ), then you'll have to look at the...
お知らせ • Feb 04Kaleido Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $60.375 million.Kaleido Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $60.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,250,000 Price\Range: $11.5
Is New 90 Day High Low • Jan 27New 90-day high: US$14.21The company is up 126% from its price of US$6.29 on 29 October 2020. The American market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period.
お知らせ • Jan 26Kaleido Biosciences, Inc. Announces Resignation of Katharine Knobil as Chief Medical Officer and Head of Research and Development, Effective as of January 29, 2021On January 20, 2021, Kaleido Biosciences, Inc. and Katharine Knobil, M.D. reached a mutual agreement that Dr. Knobil will resign from her position as Chief Medical Officer and Head of Research and Development of the Company, effective as of January 29, 2021. Dr. Knobil is leaving the Company in order to pursue other opportunities and her decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. In connection with her departure, the Company and Dr. Knobil entered into a separation agreement and general release dated as of January 25, 2021.
お知らせ • Jan 15Kaleido Biosciences, Inc. Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-To-Moderate COVID-19Kaleido Biosciences, Inc. announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 hours of testing positive for COVID-19 to either receive Supportive Self Care (SSC) or SSC plus Microbiome Metabolic Therapy (MMT™) candidate KB109 for two weeks and then followed for an additional three weeks. The planned interim analysis comprised approximately half of the total study population (n=176) and showed that KB109 was well tolerated, with a safety profile consistent with previous studies of MMT candidates and no unexpected treatment-related adverse events. For subjects reporting one or more comorbidities, the median time to resolution of the thirteen overall COVID-19 related symptoms was 18 days with KB109 plus SSC and 27 days with SSC alone. KB109 demonstrated a favorable safety and tolerability profile with no unexpected treatment-related adverse events or discontinuations related to treatment. Approximately 40 percent of the patients reported at least one comorbidity at baseline. The presence of comorbidity lengthened the time to resolution of symptoms, even in mild to moderate COVID-19 disease. In the SSC alone arm, median time to resolution of the thirteen overall COVID-19 related symptoms in patients with no comobitities was 14 days as compared with 27 days in patients with at least one comorbidity. No difference in median time to resolution of symptoms was observed with KB109 plus SSC for the overall population, although small differences between the arms were observed during the follow-up period. Median time to resolution of the thirteen overall COVID-19 related symptoms for patients with one or more comorbidity at baseline was 18 days for the KB109 plus SSC group as compared with 27 days with SSC alone. Kaleido also evaluated eight cardinal COVID-19 related symptoms as defined by the Centers for Disease Control and Prevention, which showed median time to resolution of symptoms among patients with one or more comorbidity at baseline was 15 days for the KB109 plus SSC group as compared with 27 days with SSC alone. The K031 study of 350 subjects is fully enrolled with results expected in the first quarter of 2021. Topline data from a smaller 50 subject study of KB109 is also expected in the first quarter of 2021.
Is New 90 Day High Low • Jan 08New 90-day high: US$11.40The company is up 1.0% from its price of US$11.33 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
お知らせ • Jan 05Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19Kaleido Biosciences, Inc. announced that completion of enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 in the treatment of mild-to-moderate COVID-19. The multi-center, non-IND clinical study is designed to evaluate the effects of KB109 plus supportive self-care (SSC) compared to SSC alone for outpatients who are positive for SARs-Cov-2 and have symptoms. Study endpoints include safety and tolerability, biomarkers of the inflammatory response, and time to resolution of symptoms. The Kaleido KB109 development program involves two controlled, non-IND clinical studies including one study of 350 patients evaluating symptom resolution and one study of approximately 50 patients evaluating effects on microbiome composition and biomarkers of inflammatory response. Subjects are randomized to either receive SSC (the control group) or SSC plus KB109 for two weeks and then followed for a further three weeks. KB109 was selected for evaluation in COVID-19 studies based on its ability to increase microbiome production of short chain fatty acids, which act as modulators of the immune response.
Price Target Changed • Dec 26Price target raised to US$14.00Up from US$12.60, the current price target is an average from 4 analysts. The new target price is 50% above the current share price of US$9.33. As of last close, the stock is up 69% over the past year.
分析記事 • Dec 14Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Major Estimate Revision • Nov 09Analysts update estimatesThe 2020 consensus revenue estimate increased from US$14.1m to US$18.0m. Earning per share (EPS) estimate was further reduced from -US$2.37 to -US$2.50 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 2.5% next year. The consensus price target was lowered from US$12.60 to US$11.60. Share price is up 17% to US$6.73 over the past week.
Price Target Changed • Nov 05Price target lowered to US$11.60Down from US$12.60, the current price target is an average from 4 analysts. The new target price is 81% above the current share price of US$6.40. As of last close, the stock is up 1.7% over the past year.
Analyst Estimate Surprise Post Earnings • Nov 03Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 1,101%, compared to a 32% growth forecast for the Pharmaceuticals industry in the US.
Major Estimate Revision • Oct 23Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$17.7m to US$14.1m. Earning per share (EPS) estimate was unchanged from the last update at -US$2.37. The Pharmaceuticals industry in the US is expected to see an average net income growth of 8.0% next year. The consensus price target of US$12.60 was unchanged from the last update. Share price is down by 21% to US$6.97 over the past week.
お知らせ • Oct 14Kaleido Biosciences, Inc. Announces Change of Role of Michael Bonney from Executive Chair of the Board to Chair of the BoardKaleido Biosciences, Inc. on October 9, 2020 changed Michael Bonney’s role from Executive Chair of the Board to Chair of the Board, effective as of October 13, 2020. The change in Bonney’s title was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.
お知らせ • Oct 07Kaleido Biosciences, Inc. Provides Update on KB109 Clinical Data TimelineKaleido Biosciences, Inc. announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease. Updated projections for enrollment of the multi-center K031 clinical study of approximately 350 patients indicated that top-line data will be available in the first quarter of 2021. Previous projections had indicated the potential availability of top-line data from the study in the fourth quarter of 2020. Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome’s existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company’s initial MMT candidates are targeted, synthetic glycans that are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. Kaleido utilizes its discovery and development platform to study MMTs in microbiome samples to advance MMT candidates rapidly into clinical studies in healthy subjects and patients. These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the company conducts clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., in Phase 2 or later development.
お知らせ • Oct 02+ 1 more updateKaleido Biosciences, Inc. Announces Management Changes, Effective October 13, 2020Kaleido Biosciences, Inc. announced that Daniel Menichella has been appointed President and a member of the company’s Board of Directors, effective October 13, 2020. Mr. Menichella succeeds Alison Lawton, who stepped down to attend to a family health matter but continued to work with the Company in the Office of the CEO alongside Executive Chair Mike Bonney. Mr. Menichella is an experienced Chief Executive Officer, having been hired as CEO of CureVac Inc.’s US subsidiary in January 2017 before taking over as CEO of the international company in June of 2018.
お知らせ • Sep 30Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative ColitisKaleido Biosciences, Inc. announced that the first patient has been dosed in its clinical study evaluating Microbiome Metabolic Therapy (MMT) candidate KB295 in patients with mild-to-moderate ulcerative colitis (UC). UC is an inflammatory bowel disease that can cause debilitating symptoms, including abdominal pain, bowel urgency and diarrhea. Evidence suggests that a feature of UC is alteration of the gut microbiome, including an increase in inflammatory bacteria and decrease in commensal diversity which interfere with the normal immune response. In ex vivo studies, KB295 has demonstrated the ability to increase the production of short chain fatty acids and suppress the growth of inflammatory bacteria such as Enterobacteriaceae. This non-IND/non-CTA open label, single arm clinical study is expected to enroll approximately 30 patients with mild-to-moderate UC. Patients will receive KB295 for eight weeks titrated up to 40 g twice daily and then enter a one-month follow-up period. The study will evaluate the safety and tolerability of KB295 and other assessments including the Simple Clinical Colitis Activity Index (SCCAI) composite score, changes in microbiome composition and biomarkers of inflammation.
Is New 90 Day High Low • Sep 24New 90-day low: US$5.09The company is down 35% from its price of US$7.79 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.